Skip to main content
Galapagos NV logo

Galapagos NV — Investor Relations & Filings

Ticker · GLPG ISIN · BE0003818359 LEI · 549300QKJ78IY0IOV655 BR Manufacturing
Open in API
Filings indexed 2,862 across all filing types
Latest filing 2023-12-12 Regulatory Filings
Country BE Belgium
Listing BR GLPG

About Galapagos NV

https://www.glpg.com/

Galapagos NV is a biotechnology company focused on transforming patient outcomes through scientific innovation. The company is strategically concentrating its efforts on its cell therapy platform, which is engineered for the scalable, decentralized, and rapid production of next-generation treatments. A key feature of this platform is a median 7-day vein-to-vein delivery time. In parallel with this focus, Galapagos is actively seeking partners to take over its portfolio of small molecule assets, including its TYK2 inhibitor program for autoimmune indications. This strategic shift allows the company to prioritize the growth and development of its cell therapy pipeline through internal discovery, partnerships, and acquisitions.

Recent filings

Filing Released Lang Actions
6-K Filing
Regulatory Filings
2023-12-12 English
Galapagos presents new encouraging data at ASH 2023 from ongoing CD19 CAR-T studies with GLPG5201 and GLPG5101
Earnings Release Classification · 99% confidence The document is a press release from Galapagos NV, dated December 9, 2023, announcing 'nieuwe bemoedigende resultaten' (new encouraging results) from ongoing Phase 1/2 CAR-T studies (EUPLAGIA-1 and ATALANTA-1) presented at the 65th annual meeting of the American Society of Hematology (ASH). Key indicators are: 1. **Content:** Detailed clinical trial data updates (safety, efficacy, response rates, recommended dose selection) for drug candidates (GLPG5201 and GLPG5101). 2. **Context:** Presentation at a major medical conference (ASH). 3. **Format/Length:** It is a comprehensive announcement detailing study results, not just a brief notice of publication. 4. **Exclusions:** It is not a formal regulatory filing like a 10-K, nor is it a general earnings release (ER) or a transcript (CT). This content structure—presenting detailed clinical trial data updates outside of a formal quarterly/annual report—is characteristic of an Investor Presentation (IP) or a detailed press release summarizing scientific findings, often released concurrently with an investor event or conference presentation. Given the depth of the data presentation and the context of presenting at a scientific meeting, 'Investor Presentation' (IP) is the most fitting category, as these press releases often serve as the primary communication vehicle for detailed scientific updates to the investment community when a formal IP deck might also be released or implied by the associated KOL/analyst events mentioned. It is more detailed than a standard Earnings Release (ER) and focuses purely on R&D/clinical progress, aligning best with Investor Presentation (IP). Q4 2023
2023-12-11 English
Galapagos presents new encouraging data at ASH 2023 from ongoing CD19 CAR-T studies with GLPG5201 and GLPG5101
Investor Presentation Classification · 95% confidence The document is a press release dated December 9, 2023, announcing the presentation of new clinical data from ongoing Phase 1/2 studies (EUPLAGIA-1 and ATALANTA-1) at the American Society of Hematology (ASH) Annual Meeting. It details efficacy and safety results (ORR, CRR, TEAEs) for drug candidates GLPG5201 and GLPG5101. This content—presenting detailed clinical trial results and updates outside of a formal quarterly or annual filing—is characteristic of an Investor Presentation (IP) or a detailed press release summarizing scientific findings. Since it provides substantial scientific and clinical detail intended for investors and analysts, 'Investor Presentation' (IP) is the most fitting category, as it often overlaps with the content of detailed scientific updates released outside of standard SEC forms. It is not a formal regulatory filing (like 10-K or IR), nor is it just a brief earnings release (ER).
2023-12-11 English
Galapagos to Host KOL Event on December 10, 2023, at 11:00 AM PST to discuss new data presented at ASH 2023
Regulatory Filings Classification · 99% confidence The document is a press release dated December 6, 2023, announcing a Key Opinion Leader (KOL) event scheduled for December 10, 2023, to discuss new data presented at ASH 2023 regarding GLPG5201 and GLPG5101 clinical studies. This is an announcement about an upcoming event where company information (clinical data review) will be presented, featuring KOLs and company leadership. It is not a full financial report (10-K, IR), a transcript of a call (CT), or a formal regulatory filing like an ER or MRQ. It is an announcement intended for investors and the public regarding a specific corporate/scientific event. This fits best under the category of Investor Presentation (IP) if it were the presentation itself, but since it is an *announcement* of an event where presentations will occur, and given the context of corporate communications, it most closely aligns with a general announcement or investor relations material. However, since the content is focused on clinical data review and future outlook discussions, it is a form of investor communication. Given the options, it is an announcement of an event that will feature scientific/clinical updates, which often accompanies or precedes an Investor Presentation (IP). Since it is an announcement *about* an event, and not the event transcript or the presentation slides themselves, it functions as a general corporate update. If the event were a standard earnings call, it would be an ER or CT. Since it is a scientific/KOL event announcement, it is a specific type of investor communication. It is not a standard regulatory filing (RNS) unless no other category fits. Given the focus on clinical data and KOL review, it is highly relevant to investors. It is not a proxy statement (DEF 14A), a dividend notice (DIV), or a management discussion (MDA). The closest fit for an announcement detailing upcoming scientific/clinical updates for investors, outside of a formal earnings release, is often categorized as an Investor Presentation (IP) announcement or a general Regulatory Filing (RNS). Since it is a specific announcement about an event that will present data, and not a general regulatory filing, and it is not the presentation itself, I will classify it as a general Regulatory Filing (RNS) as a broad communication, or consider if it implies an Investor Presentation (IP) is forthcoming. Given the nature of the announcement (KOL event discussing clinical data), it is a form of investor relations material. Since there is no specific code for 'Event Announcement', RNS is the fallback for non-standard announcements. However, if we interpret 'Investor Presentation' (IP) broadly to include the announcement of such an event where detailed data is reviewed, it might fit. Given the strong focus on clinical data review by KOLs, it is a key investor communication. I will lean towards RNS as the safest general regulatory/corporate announcement category, as it is not the presentation itself, nor a transcript, nor a financial report. Re-evaluating: This is a press release announcing an event where data will be discussed. This is a standard corporate communication. RNS is the best fit for general corporate announcements that don't fit elsewhere, especially when they are not the final report/transcript/release itself. I will assign RNS with high confidence as a general corporate/investor announcement.
2023-12-08 English
Galapagos to Host KOL Event on December 10, 2023, at 11:00 AM PST to discuss new data presented at ASH 2023
Investor Presentation Classification · 90% confidence The document is a press release, written in Dutch, announcing a Key Opinion Leader (KOL) event scheduled for December 10, 2023, to discuss new data presented at ASH 2023 regarding their CAR-T studies (GLPG5201 and GLPG5101). It details the speakers (KOLs and Galapagos management) and the topics to be covered. This type of announcement, which publicizes an upcoming event where financial/scientific updates will be discussed, is typically classified as an Investor Presentation (IP) if the presentation materials themselves were attached, or an Earnings Release (ER) if it were summarizing period results. However, since this is an announcement *about* an upcoming event where data will be discussed, and it is not a formal regulatory filing like a 10-K or a standalone earnings summary, it most closely aligns with an announcement related to investor communication or a presentation event. Given the options, it is a specific announcement about an investor/scientific event, which often precedes or is related to an Investor Presentation (IP). Since it is an announcement of an event where data will be presented, and not the presentation itself, it could potentially be an RPA, but the content is highly specific to investor/scientific updates rather than just announcing the publication of a report. Because it details an event where management will provide updates and KOLs will discuss clinical data, it functions as a precursor or context for investor information. In the context of financial filings, announcements about specific scientific/investor events are often grouped with Investor Presentations (IP) or sometimes Earnings Releases (ER) if they are tied to results. Given the focus on clinical data discussion with KOLs, 'Investor Presentation (IP)' is the most fitting category for the *subject matter* being communicated, even if this specific document is the *invitation/announcement* for that event. However, following Rule 2 (The 'MENU VS MEAL' Rule), if this document is short and only announces the event, it should be RPA or RNS. The document length is 15,321 characters, which is substantial, suggesting it contains more than just a brief announcement link. It provides extensive context about the studies and the speakers' backgrounds. This level of detail suggests it is more than a simple 'Report Publication Announcement' (RPA). It is a detailed communication aimed at investors/analysts about upcoming data review. In many databases, detailed announcements about scientific/investor events are classified as Investor Presentations (IP) or sometimes Earnings Releases (ER) if they relate to period results. Since this is focused on clinical data review at a conference, IP is the best fit for the *type* of information being disseminated, even if it's the announcement itself.
2023-12-08 Dutch
S-8 Filing
Regulatory Filings
2023-12-04 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.